The prognostic value of EGFR overexpression and amplification in Esophageal squamous cell Carcinoma

Background In view of the prominent role in cancer cell biology and alteration in substantial numbers of ESCC, defining EGFR molecular characteristics relevant to patient prognosis is of great importance. Therefore, we analyzed the protein expression and gene copy variation of the epithelial growth factor receptor (EGFR) in Chinese esophageal squamous cell carcinoma (ESCC) and explored the possible associations with various features of the tumors and survival of the patients. Methods Sections were made from tissue microarray composed of 96 ESCC, and examined for EGFR expression by means of immunohistochemistry (IHC) and for EGFR gene amplification by means of fluorescence in situ hybridization (FISH). The results of IHC were evaluated with six different reported scoring systems. Correlation with clinical features and survival was evaluated using chi-square test and Kaplan–Meier analysis. Results EGFR overexpression according to scoring system 1 significantly correlated with advanced lymph node involvement (P = 0.046), patient disease specific free survival (DFS) (P = 0.006) and overall survival (OS) (P = 0.007). No such association was observed using other 5 scoring systems (P > 0.05 ). EGFR amplification was associated with lymph node metastasis (P = 0.028), but not correlated with DFS and OS until 20 months. Conclusions EGFR IHC overexpression evaluated by scoring system 1 might be suitable to be used in predicting patients survival in ESCC. EGFR gene amplification showed delayed prognostic information after 20 months. Electronic supplementary material The online version of this article (doi:10.1186/s12885-015-1393-8) contains supplementary material, which is available to authorized users.


Background
Esophageal carcinoma is one of the most common malignancies in China, and squamous cell carcinoma is the main histological type [1,2]. It generally has a poor prognosis because it is usually in an advanced stage at the time of diagnosis. Despite the progress in chemotherapeutic, radiotherapeutic and surgical treatment, the five-year survival rate is still less than 20 % [3][4][5][6]. In recent years, molecular targeted therapy has become an important treatment [7][8][9][10]. With the aim of increasing the clinical benefit-risk ratio of anticancer treatments, consideration is increasingly given to the identification of predictive tumour biomarkers.
One potential group of useful protein biomarkers is the epidermal growth factor receptor (EGFR) family of receptors. This family contains four members, EGFR, ErbB2/human epidermal growth factor receptor-2 (HER2), ErbB3/HER3, and ErbB4/HER4, that act as receptor tyrosine kinases and have a well-defined function in cell signaling, controlling cell proliferation and differentiation. Esophageal cancers frequently show EGFR or HER2 gene amplification and overexpression [11,12]. And esophageal squamous cell carcinomas (ESCCs) predominantly show alterations of EGFR, whereas esophageal (Barrett's) adenocarcinomas (EACs) frequently show HER2 gene amplification and protein overexpression. In view of the prominent role in cancer cell biology and (over-)expression in substantial numbers of ESCC, EGFR represents valuable therapeutic target. Defining EGFR molecular characteristics relevant to patient prognosis is an important step toward deciding treatment.
At present, the literatures about EGFR expression in ESCC contain conflicting data on the relationship between overexpression and survival [13][14][15]. This variability may be due to heterogeneity of study populations or lack of a standardized assay for determining EGFR status. Here, we collected a cohort of Chinese patients with ESCC, and evaluated their protein expression using 6 representative scoring systems. To the best of our knowledge and available literature data, so far such comparisons of different EGFR-IHC scoring systems in ESCC patients are sparse.
EGFR gene copy number variation may be more reliable than protein expression in predicting prognosis. However, reports on the influence of EGFR gene variation in ESCC patients have been equivocal [13,[16][17][18]. In general, the relationships between tumor EGFR gene variation and protein expression have not been clearly defined, and the prognostic value of these tumor characteristics has not been well evaluated for ESCC.
Therefore, the aims of this study are to compare the six different scoring systems for EGFR expression, to explore the cut off value in assessing EGFR gene variation, and to investigate their prognostic significance in ESCC.

Patients and specimens
A total of 96 ESCC samples were treated in the Department of Thorax Surgery, Zhongshan Hospital during March to October 2010. All patients had not received chemotherapy or radiotherapy prior to surgical resection. Prior written informed consent was obtained from all patients. The present study has been carried out in accordance with the Declaration of Helsinki, and was approved by Human Research Ethics Committee of Zhongshan hospital, Fudan University.
Sections were stained with hematoxylin and eosin and reviewed by two pathologists to confirm the ESCC diagnosis. The following patient characteristics were collected: gender, age, tumor site (upper, middle, and lower region of esophagus), histological grade, coagulative necrosis, nerve and vascular infiltration, mitotic index (numbers recorded as ≤20 per 10 high power fields [HPF], 20-50/10HPF, or ≥ 50/10HPF), lymph node metastasis, and stage, as previously reported [19].

Tissue microarrays
The tissue microarray (TMA) was constructed as previously described [20]. Briefly, the region of interest (2 mm wide and 6 mm long) was extracted and then vertically planted into the recipient block one by one according to the corresponding location indicated by letters and numbers. The planting surface was aggregated on the aggregation instrument.

Immunohistochemistry
The TMA recipient block was sectioned on a routine microtome machine. The IHC assay using EGFR rabbit monoclonal antibody (EGFR.25, Leica Biosystems Newcastle Ltd, Newcastle, UK) was performed with the Ventana iView DAB Detection Kit on a BenchMark XT automated staining system (Ventana Medical Systems, Tucson, AZ). Normal IgG from the same species of primary antibody diluted to match the concentration of the primary antibody was used as the negative control. For EGFR negative cases, the experiment was repeated on the whole section in order to exclude heterogeneity.

Fluorescence in situ hybridization
TMA sections were dewaxed and dehydrated. Dual color EGFR FISH was performed with the Spectrum Orange locus-specific identifier EGFR probe (Vysis, Abbott Molecular Inc, Des plaines, USA) specific for the EGFR locus (7p12) and the Spectrum Green CEP7 chromosome 7 centromeric probe (7p11.1 to q11.1; Vysis). The specific steps were similar to HER2-FISH procedure, reported previously [26]. EGFR signals were counted from at least 100 cancer cell nuclei, and were divided into six types: 1) disomy was an EGFR to CEP7 ratio ≤2 copies in >90 % of cells; 2) low trisomy was ≤2 copies in ≥40 % of cells, 3 copies in 10 %-40 % of the cells, ≥4 copies in <10 % of cells; 3) high trisomy was ≤2 copies in ≥40 % of cells, 3 copies in >40 % of cells, ≥4 copies in <10 % of cells; 4) low polysomy was ≥4 copies in 10 %-40 % of cells; 5) high polysomy was ≥4 copies in >40 % of cells; 6) gene amplification was defined by the presence of tight EGFR gene clusters, or a ratio of EGFR gene to chromo-some7 ≥ 2, or ≥15 copies of EGFR per cell in ≥10 % of tumor cells. EGFR FISH-positive was defined as EGFR high polysomy or gene amplification [27].

Follow-up information
Follow-up information for the 96 patients after surgery and treatment was provided by the referring clinicians, or else obtained directly from patients and their family members as standard procedure. The date of last follow up was May 16, 2014. Disease-free survival (DFS) and overall survival (OS) were measured from the time of surgery to the time of first recurrence (or most recent follow-up) or death.

Statistical analysis
A χ2 test was used for univariate analysis, the agreement of different scoring systems was measured by the index Kappa and the statistical differences were analyzed by the McNemar test. Kaplan-Meier analysis was used to calculate DFS and OS. Log-rank test of survival analysis was used to compare DFS and OS as functions of variables and to identify significant differences. P < 0.05 were recorded as significant.

Characterization of ESCC patients
The clinicopathological features of the 96 ESCC patients are summarized previously [28]. The majority of the patients were males (83.3 %). The median age of patients was 62 years. By anatomic site, 1 was located in the upper esophagus, 33 in the middle and 62 in the lower area. Most of the tumor differentiation was grade II (63.5 %), 36.5 % was grade III and none was grade 1. Five tumors had invaded to the submucosa, 24 to the muscularis propria and 67 to the adventitia. Fifty-three tumors were associated with nerve or vascular infiltration and 44 with lymph node metastases.

EGFR IHC analysis
Among the 96 ESCC cases analyzed, the EGFR IHC staining results are evaluated using six scoring systems (Additional file 1: Table S1). The scoring system 1 and 6 has low, intermediate and high level of EGFR expression, while 2, 3, 4 and 5 only has low and high level (Table 1).  Table S1). Fig. 1a showed the negative control, 1b, 1c, and 1d were low, intermediate and high level of EGFR expression according to system 1.
There were significant difference among the six IHC score results (P < 0.001) ( Table 1). The scoring system 2 and 3 are highly in agreement with each other (k = 0.87). No comparison could be conducted between 1 and 4.

EGFR gene copy variation
The average gene copy number per cell and the EGFR-tochromosome 7 ratio for the major FISH patterns are listed in Additional file 2: Table S2. EGFR FISH-positive was seen in 29 (30.2 %) cases. The EGFR genes were amplified in 7 (7.3 %) cases (6 were clustered-type signals and 1 were multiple scattered signals) (Figs. 2a and b). High polysomy (≥4 copies in >40 % of cells) was present in the other 22 (22.9 %) cases, with the averages of EGFR and chromosome 7 signals per cell ranging between 3.11 and 5.10 and the gene-to-chromosome ratio ranging from 0.82 to 1.84 (Fig. 2c). Low polysomy was present in 39 (40.6 %) cases with the averages of gene and chromosome copies per cell ranging from 2.43 to 3.27 and the chromosome-to-gene ratio ranging from 0.92 to 1.14 ( Fig. 2d), disomy in 3 (3.1 %) cases, with the averages per cell for the gene and chromosome 7 copies ranging from 2.02 to 2.17 and the ratio of gene-to-chromosome from 0.97 to 1.04 (Fig. 2f ), low trisomy in 19 (19.8 %) cases with the averages per cell for the gene and chromosome 7 copies ranging from 1.95 to 2.49 and the ratio of gene-to-chromosome from 0.74 to 1.12, and high trisomy in 6 (6.3 %) cases with the averages per cell for the gene and chromosome 7 copies ranging from 2.56 to 2.91 and the ratio of gene-to-chromosome from 0.95 to 1.02 (Fig. 2e). These cases were categorized as a FISH-negative group.

Correlation between EGFR protein expression and gene variation
EGFR expression and gene copy number are analyzed and showed in Table 2. EGFR gene amplification was associated with EGFR protein overexpression in scoring system 1, 2, 3, 4, and 6, EGFR-FISH positive only in scoring system 1, 2 and 4. On the basis of scoring system 1, 3 and 4, patients with trisomy and polysomy showed low mean IHC scores (206 and 197, 6.6 and 6.5, 94.6 and 100 respectively), whereas the mean IHC score increased when FISH abnormalities became more severe. The mean score was 348.6, 13.7 and 254.3 for patients with gene amplification (Additional file 3: Table S3).

Prognostic implication of EGFR protein expression levels and gene variation
EGFR protein overexpression and gene amplification were statistically evaluated for correlation with established clinicopathological factors (Table 3). EGFR overexpression according to scoring system 1 and 4 was significantly correlated with the vascular invasion, lymph node metastasis (P < 0.05, Table 3). No such correction was observed using other scoring systems. EGFR amplification was associated with the lymph node metastasis (P = 0.028), while high polysomy wasn't associated with this factor (P = 0.227).
EGFR overexpression and gene amplification were evaluated for their potential prognostic significance. The Kaplan-Meier survival curves for patients in the different scoring systems of EGFR expression or gene numbers are shown in Figs. 3 and 4. Protein overexpression, on the basis of scoring system 1, had poorer DFS (P = 0.006) (Fig. 3a) and OS (P = 0.004) (Fig. 3b). However, other systems had no prognostic value whether in DFS or in OS (Fig. 3c and d). And gene amplification did not represent a statistically significant adverse prognosis until 20 months (Fig. 4). No significant difference in survival rates with respect to high polysomy was observed.

Discussion
The epithelial growth factor receptor (EGFR) is a 170-kDa transmembrane glycoprotein and a tyrosine kinase receptor expressed in various human tissues, especially in cells of epithelial origin, which plays important roles in modulating cell proliferation, survival, migration, and differentiation [29]. EGFR alterations in cancer can be divided mostly in two categories: mutations in exons 18-21 mainly identified in Asia lung adenocarcinoma [30,31], and gene and protein overexpression [32]. It's known to us, ESCC predominantly show EGFR gene copy number alterations and protein overexpression [11,13,24,33], with little EGFR mutation [16,26,34]. EGFR gene variation and protein overexpression might be the candidate for predictive biomarker in ESCC. There have been several IHC studies examining EGFR protein expression in ESCC, the expression rate ranged from 4 % to 86 % [13,24,33]. We found the most important discrepancies might be due to the selected threshold for positivity, which may induce conflicting results in different laboratories and authors. Therefore, we selected six different scoring systems presented in literature to focus upon the same ESCC samples with EGFR antibody.

Evaluation of EGFR expression by six scoring systems in ESCC
Firstly, the overexpression of EGFR were observed in 8 (8.3 %), 64 (66.7), 48 (50 %), 8 (8.3 %), 84 (87.5 %), and 49 (51.0 %) cases according to system 1 to 6, with ranging from 8.3 % to 87.5 %. These results were in agreement with our speculation that EGFR expression was obviously influenced by the selected threshold. Secondly, the correlation of EGFR expression with clinical features and prognosis were evaluated by scoring system 1 to 6, 1 and 4 related to lymph node metastasis, however, only 1 showed a statistically significant prognosis with DFS (0.006) and OS (0.007). Therefore, scoring system 1 for EGFR expression seems to be more valuable for predicting tumor aggressiveness and prognosis.

Evaluation of EGFR gene variation in ESCC
Firstly, EGFR gene status disclosed by our FISH included disomy, low trisomy, high trisomy, low polysomy, high polysomy and gene amplification, which was consistent with previous reports [24]. Secondly, EGFR gene amplification was associated with EGFR expression evaluated by scoring system 1, 2, 3, 4, 6 except 5, whereas EGFR-FISH positive was only associated with scoring system 1, 2 and 4. Thirdly, EGFR-FISH positive had no relationship with clinical features and prognosis; however, EGFR amplification was associated with lymph node metastasis, and patients with EGFR amplification had poorer prognosis whether in DFS or OS after 20 months survival. Therefore, EGFR amplification, not EGFR-FISH positive or high polysomy, seems to be a suitable cut off value in clinical practice.